Table 3. Prevalence and odds ratio (OR) associated with adherence for each of the methods used.
|
Physician report
|
Telephone questionnaire
|
Pharmacy administrative database
|
||||
|---|---|---|---|---|---|---|
| n (%) | ORa | n (%) | ORb | n (%) | ORc | |
| Age at diagnosis | ||||||
| ⩽49 | 183 (90.7) | 1 | 138 (84.8) | 1 | 176 (64.8) | 1 |
| 50–74 | 419 (95.5) | 1.71 (0.72–4.06) | 330 (94.2) | 2.75 (1.41–5.36)a | 409 (79.0) | 1.67 (1.03–2.70)a |
| ⩾75 | 90 (94.4) | 2.56 (0.68–9.63) | 38 (86.8) | 1.07 (0.37–3.12) | 88 (67.0) | 1.60 (0.76–3.36) |
| P-value | 0.075 | 0.003a | 0.001a | |||
| Stage | ||||||
| I | 321 (93.5) | 1 | 249 (92.8) | 1 | 314 (74.2) | 1 |
| IIA | 200 (95.0) | 0.89 (0.36–2.19) | 142 (90.1) | 0.81 (0.38–1.71) | 192 (78.1) | 1.09 (0.67–1.77) |
| IIB | 93 (93.5) | 0.72 (0.25–2.1) | 64 (87.5) | 0.63 (0.25–1.56) | 91 (64.8) | 0.57 (0.32–1)a |
| IIIA | 42 (95.2) | 1.2 (0.24–5.96) | 30 (90.0) | 0.62 (0.16–2.33) | 40 (77.5) | 1.09 (0.46–2.58) |
| TNMx | 36 (94.4) | 1.01 (0.2–5.09) | 21 (90.5) | 0.87 (0.17–4.50) | 36 (63.9) | 0.67 (0.29–1.58) |
| P-value | 0.953 | 0.718 | 0.101 | |||
| Surgical treatment | ||||||
| Yes | 681 (94.1) | 1 | 505 (91.1) | 1 | 663 (74.2) | 1 |
| No | 11 (90.9) | 1.63 (0.16–17.14) | 1 (100.0) | — | 10 (40.0) | 2.14 (0.51–8.98) |
| P-value | 0.654 | 0.911 | 0.015a | |||
| Type of surgical treatment | ||||||
| Conservative breast surgery | 536 (93.7) | 1 | 394 (91.4) | 1 | 523 (74.8) | 1 |
| Radical breast surgery | 145 (95.9) | 1.34 (0.51–3.5) | 111 (90.1) | 1.09 (0.50–2.34) | 140 (72.1) | 1.47 (0.80–2.68) |
| P-value | 0.426 | 0.706 | 0.516 | |||
| Radiotherapy | ||||||
| No | 132 (91.7) | 1 | 85 (91.8) | 1 | 128 (62.5) | 1 |
| Yes | 560 (94.6) | 1.8 (0.8–4.05) | 421 (91.0) | 0.65 (0.27–1.57) | 545 (76.3) | 1.48 (0.93–2.36) |
| P-value | 0.193 | 0.815 | 0.001a | |||
| Neoadjuvant chemotherapy | ||||||
| No | 598 (94.1) | 1 | 445 (90.8) | 1 | 582 (74.6) | 1 |
| Yes | 94 (93.6) | 0.79 (0.28–2.2) | 61 (93.4) | 1.79 (0.59–5.44) | 91 (68.1) | 0.57 (0.33–1) |
| P-value | 0.840 | 0.494 | 0.195 | |||
| Adjuvant chemotherapy | ||||||
| No | 331 (92.1) | 1 | 231 (91.8) | 1 | 322 (68.6) | 1 |
| Yes | 361 (95.8) | 2.14 (1.01–4.53)a | 275 (90.5) | 0.89 (0.44–1.81) | 351 (78.3) | 1.60 (1.05–2.43)a |
| P-value | 0.039a | 0.628 | 0.004a | |||
| Endocrine therapy | ||||||
| Tamoxifen | 200 (89.0) | 1 | 136 (89.7) | 1 | 193 (60.6) | 1 |
| Inhibitors | 206 (94.7) | 2.06 (0.82–5.17) | 142 (90.9) | 0.53 (0.19–1.48) | 201 (78.1) | 2 (1.18–3.38)a |
| Tamoxifen + inhibitors | 243 (98.4) | 6.28 (1.93–20.45)a | 197 (92.9) | 0.65 (0.26–1.64) | 238 (84.5) | 2.27 (1.34–3.84)a |
| Others | 43 (94.1) | 1.24 (0.38–4.03) | 31 (87.1) | 0.52 (0.15–1.84) | 41 (51.2) | 0.55 (0.27–1.13) |
| P-value | <0.001a | 0.630 | <0.001a | |||
| Side effects b | ||||||
| No | 309 (92.2) | 1 | 209 (90.9) | 1 | 298 (69.5) | 1 |
| Yes | 383 (95.6) | 1.81 (0.81–4.02) | 297 (91.2) | 1.06 (0.49–2.28) | 375 (77.1) | 1.25 (0.81–1.93) |
| P-value | 0.048a | 0.508 | 0.016a | |||
Abbreviations: ORa=adjusted for centre, age at diagnosis, adjuvant chemotherapy, adverse effects and endocrine therapy; ORb=adjusted for centre, age at diagnosis; ORc=adjusted for centre, age at diagnosis, adjuvant chemotherapy, radiotherapy, side effects and endocrine therapy.
n (%)=number of cases (% adherence); P-value: χ2-test.
a
Statistical significance, P<0.05.
b
Adverse effects of physician report.